Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

Nenhuma Miniatura disponível
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER INC
Autores
LANDOVITZ, Raphael J.
HANSCOM, Brett S.
CLEMENT, Meredith E.
V, Ha Tran
MAGNUS, Manya
SUED, Omar
SANCHEZ, Jorge
SCOTT, Hyman
ERON, Joe J.
Citação
LANCET HIV, v.10, n.12, p.E767-E778, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Injectable cabotegravir was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in two clinical trials. Both trials had the primary aim of establishing the HIV prevention efficacy of long acting injectable cabotegravir pre-exposure prophylaxis (PrEP) compared with tenofovir disoproxil fumarate plus emtricitabine daily oral PrEP. Long-acting PrEP was associated with diagnostic delays and integrase strand-transfer inhibitor (INSTI) resistance. This report presents findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study. Methods The HPTN 083 randomised controlled trial enrolled HIV-uninfected cisgender men and transgender women at elevated HIV risk who have sex with men, from 43 clinical research sites in Africa, Asia, Latin America, and the USA. Inclusion criteria included: a negative HIV serological test at the screening and study entry, undetectable HIV RNA levels within 14 days of study entry, age 18 years or older, overall good health as determined by clinical and laboratory evaluations, and a creatinine clearance of 60 mL/min or higher. Participants were randomly allocated to receive long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP. After study unblinding, participants remained on their original regimen awaiting an extension study. HIV infections were characterised retrospectively at a central laboratory. Here we report the secondary analysis of efficacy and safety for the first unblinded year. The primary outcome was incident HIV infection. Efficacy analyses were done on the modified intention-to-treat population using a Cox regression model. Adverse events were compared across treatment groups and time periods (blinded vs unblinded). This trial is registered with ClinicalTrials.gov, NCT02720094. Findings Of the 4488 participants who contributed person-time to the blinded analysis, 3290 contributed person-time to the first unblinded year analysis between May 15, 2020, and May 14, 2021. Updated HIV incidence in the blinded phase was 0 center dot 41 per 100 person-years for long-acting injectable cabotegravir PrEP and 1 center dot 29 per 100 person-years for daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP (hazard ratio [HR] 0 center dot 31 [95% CI 0 center dot 17-0 center dot 58], p=0 center dot 0003). HIV incidence in the first unblinded year was 0 center dot 82 per 100 person-years for long-acting PrEP and 2 center dot 27 per 100 person-years for daily oral PrEP (HR 0 center dot 35 [0 center dot 18-0 center dot 69], p=0 center dot 002). Adherence to both study products decreased after study unblinding. Additional infections in the long-acting PrEP group included two with on-time injections; three with one or more delayed injections; two detected with long-acting PrEP reinitiation; and 11 more than 6 months after their last injection. Infection within 6 months of cabotegravir exposure was associated with diagnostic delays and INSTI resistance. Adverse events were generally consistent with previous reports; incident hypertension in the long-acting PrEP group requires further investigation. Interpretation Long-acting injectable cabotegravir PrEP retained high efficacy for HIV prevention in men and transgender women who have sex with men during the first year of open-label follow-up, with a near-identical HR for HIV risk reduction between long-acting injectable cabotegravir and daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP during the first year after unblinding compared with the blinded period. Extended follow-up further defined the risk period for diagnostic delays and emergence of INSTI resistance. Funding Division of AIDS at the National Institute of Allergy and Infectious Diseases, ViiV Healthcare, and Gilead Sciences.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/57947
Referências
  1. Anderson PL, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01710-17
  2. Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/aid.2012.0089, 10.1089/AID.2012.0089]
  3. Centers for Disease Control and Prevention, 2021, US PUBLIC HLTH SERVI
  4. Delany-Moretlwe S, 2022, LANCET, V399, P1779, DOI 10.1016/S0140-6736(22)00538-4
  5. Eshleman SH, 2022, J INFECT DIS, V226, P2170, DOI 10.1093/infdis/jiac415
  6. Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
  7. Han KL, 2022, BRIT J CLIN PHARMACO, V88, P4607, DOI 10.1111/bcp.15439
  8. Hendrix CW, 2016, AIDS RES HUM RETROV, V32, P32, DOI [10.1089/aid.2015.0182, 10.1089/AID.2015.0182]
  9. Hodge D, 2021, CLIN PHARMACOKINET, V60, P835, DOI 10.1007/s40262-021-01005-1
  10. Landovitz RJ, 2021, NEW ENGL J MED, V385, P595, DOI 10.1056/NEJMoa2101016
  11. Landovitz RJ, 2020, LANCET HIV, V7, pE472, DOI 10.1016/S2352-3018(20)30106-5
  12. Marzinke MA, 2023, ANTIMICROB AGENTS CH, V67, DOI 10.1128/aac.00053-23
  13. Marzinke MA, 2021, J INFECT DIS, V224, P1581, DOI 10.1093/infdis/jiab152
  14. Mutebi RK, 2023, INTEGR BLOOD PRESS C, V16, P11, DOI 10.2147/IBPC.S403023
  15. Torres TS, 2023, Recent HIV infection and annualized HIV incidence rates among sexual and gender minorities in Brazil and Peru (ImPrEP seroincidence study): a cross-sectional, multicenter study
  16. U.S. Food and Drug Administration, 2021, FDA approves first injectable treatment for HIV pre-exposure prevention
  17. US Department of Health and Human Services National Institute of Allergy and Infectious Diseases Division of AIDS, Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events
  18. Veloso VG, 2023, LANCET HIV, V10, pE84, DOI 10.1016/S2352-3018(22)00331-9
  19. ViiV Healthcare, 2021, APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use: US prescribing information
  20. Yáñez JA, 2011, THER DELIV, V2, P643, DOI [10.4155/TDE.11.19, 10.4155/tde.11.19]

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/60
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/05